دورية أكاديمية
أعرض في EDS

Organic Selenium Reaches the Central Nervous System and Downmodulates Local Inflammation: A Complementary Therapy for Multiple Sclerosis?

التفاصيل البيبلوغرافية
العنوان: Organic Selenium Reaches the Central Nervous System and Downmodulates Local Inflammation: A Complementary Therapy for Multiple Sclerosis?
المؤلفون: de Toledo JHDS; Department of Chemical and Biological Sciences, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, Brazil., Fraga-Silva TFC; Department of Chemical and Biological Sciences, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, Brazil., Borim PA; Department of Chemical and Biological Sciences, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, Brazil., de Oliveira LRC; Department of Chemical and Biological Sciences, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, Brazil., Oliveira EDS; Department of Chemical and Biological Sciences, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, Brazil., Périco LL; Department of Structural and Functional Biology, São Paulo State University (UNESP), Institute of Biosciences, Botucatu, Brazil., Hiruma-Lima CA; Department of Structural and Functional Biology, São Paulo State University (UNESP), Institute of Biosciences, Botucatu, Brazil., de Souza AAL; Veterinary Clinical Laboratory, School of Veterinary Medicine and Animal Science (FMVZ), São Paulo State University (UNESP), Botucatu, Brazil., de Oliveira CAF; Department of Research and Development, Biorigin Company, Lençóis Paulista, Brazil., Padilha PM; Department of Chemical and Biological Sciences, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, Brazil., Pinatto-Botelho MF; LabSSeTe Department of Fundamental Chemistry, Institute of Chemistry, University of São Paulo (USP), São Paulo, Brazil., Dos Santos AA; LabSSeTe Department of Fundamental Chemistry, Institute of Chemistry, University of São Paulo (USP), São Paulo, Brazil., Sartori A; Department of Chemical and Biological Sciences, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, Brazil., Zorzella-Pezavento SFG; Department of Chemical and Biological Sciences, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, Brazil.
المصدر: Frontiers in immunology [Front Immunol] 2020 Oct 30; Vol. 11, pp. 571844. Date of Electronic Publication: 2020 Oct 30 (Print Publication: 2020).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: Anti-Inflammatory Agents/*therapeutic use , Central Nervous System/*drug effects , Encephalomyelitis, Autoimmune, Experimental/*drug therapy , Inflammasomes/*metabolism , Microglia/*pathology , Multiple Sclerosis/*drug therapy , Neurogenic Inflammation/*drug therapy , Selenium/*therapeutic use, Animals ; Central Nervous System/pathology ; Disease Models, Animal ; Encephalomyelitis, Autoimmune, Experimental/immunology ; Humans ; Lactic Acid/chemistry ; Male ; Mice ; Mice, Inbred C57BL ; Multiple Sclerosis/immunology ; Myelin-Oligodendrocyte Glycoprotein/immunology ; NLR Family, Pyrin Domain-Containing 3 Protein/metabolism ; Neurogenic Inflammation/immunology ; Selenium/chemistry
مستخلص: Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system (CNS). The persistent inflammation is being mainly attributed to local oxidative stress and inflammasome activation implicated in the ensuing demyelination and axonal damage. Since new control measures remain necessary, we evaluated the preventive and therapeutic potential of a beta-selenium-lactic acid derivative (LAD-βSe), which is a source of organic selenium under development, to control experimental autoimmune encephalomyelitis (EAE) that is an animal model for MS. Two EAE murine models: C57BL/6 and SJL/J immunized with myelin oligodendrocyte glycoprotein and proteolipid protein, respectively, and a model of neurodegeneration induced by LPS in male C57BL/6 mice were used. The preventive potential of LAD-βSe was initially tested in C57BL/6 mice, the chronic MS model, by three different protocols that were started 14 days before or 1 or 7 days after EAE induction and were extended until the acute disease phase. These three procedures were denominated preventive therapy -14 days, 1 day, and 7 days, respectively. LAD-βSe administration significantly controlled clinical EAE development without triggering overt hepatic and renal dysfunction. In addition of a tolerogenic profile in dendritic cells from the mesenteric lymph nodes, LAD-βSe also downregulated cell amount, activation status of macrophages and microglia, NLRP3 (NOD-like receptors) inflammasome activation and other pro-inflammatory parameters in the CNS. The high Se levels found in the CNS suggested that the product crossed the blood-brain barrier having a possible local effect. The hypothesis that LAD-βSe was acting locally was then confirmed by using the LPS-induced neurodegeneration model that also displayed Se accumulation and downmodulation of pro-inflammatory parameters in the CNS. Remarkably, therapy with LAD-βSe soon after the first remitting episode in SJL/J mice, also significantly downmodulated local inflammation and clinical disease severity. This study indicates that LAD-βSe, and possibly other derivatives containing Se, are able to reach the CNS and have the potential to be used as preventive and therapeutic measures in distinct clinical forms of MS.
(Copyright © 2020 Toledo, Fraga-Silva, Borim, de Oliveira, Oliveira, Périco, Hiruma-Lima, de Souza, de Oliveira, Padilha, Pinatto-Botelho, dos Santos, Sartori and Zorzella-Pezavento.)
References: PLoS One. 2015 May 12;10(5):e0125836. (PMID: 25965341)
J Lab Clin Med. 1975 Feb;85(2):337-41. (PMID: 803541)
Cell Res. 2014 Jan;24(1):24-41. (PMID: 24366339)
J Neuropathol Exp Neurol. 2018 Mar 1;77(3):178-192. (PMID: 29342287)
Eur J Immunol. 2009 Aug;39(8):2036-9. (PMID: 19672899)
Mult Scler. 2014 Oct;20(11):1425-31. (PMID: 24842957)
J Neurosci. 2012 Aug 22;32(34):11706-15. (PMID: 22915113)
Nat Rev Neurosci. 2018 Oct;19(10):610-621. (PMID: 30206330)
Nat Rev Neurol. 2019 Jun;15(6):329-342. (PMID: 31000816)
Brain Res Bull. 2015 Mar;112:25-34. (PMID: 25596423)
Nat Rev Dis Primers. 2018 Nov 8;4(1):43. (PMID: 30410033)
Methods Enzymol. 1985;113:548-55. (PMID: 4088074)
Mediators Inflamm. 2014;2014:590409. (PMID: 24692851)
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5409-14. (PMID: 24706865)
J Neuroinflammation. 2015 Jun 06;12:114. (PMID: 26048578)
Anal Sci. 2006 Jun;22(6):861-4. (PMID: 16772686)
IUBMB Life. 2012 Nov;64(11):863-71. (PMID: 23086812)
Trends Mol Med. 2013 May;19(5):309-19. (PMID: 23582699)
Front Cell Neurosci. 2018 Apr 27;12:114. (PMID: 29755324)
Front Immunol. 2018 Jan 18;8:2012. (PMID: 29403486)
Neuroscience. 2016 Mar 11;317:130-40. (PMID: 26762804)
Cell. 2010 Mar 19;140(6):821-32. (PMID: 20303873)
Nat Rev Immunol. 2015 Sep 15;15(9):545-58. (PMID: 26250739)
J Autoimmun. 2018 Jan 21;:. (PMID: 29395738)
Endocrine. 2015 Apr;48(3):756-75. (PMID: 25519493)
J Neurosci Res. 2016 Oct;94(10):907-14. (PMID: 27312674)
Antioxid Redox Signal. 2015 May 1;22(13):1111-29. (PMID: 25330206)
Nat Rev Drug Discov. 2010 Nov;9(11):883-97. (PMID: 21031003)
Metallomics. 2015 Aug;7(8):1213-28. (PMID: 25996565)
Exp Neurol. 2016 Mar;277:58-67. (PMID: 26626971)
J Autoimmun. 2017 Aug;82:13-30. (PMID: 28624334)
Br J Nutr. 2012 Nov 28;108(10):1829-38. (PMID: 22273003)
Front Immunol. 2011 Jul 01;2:25. (PMID: 22566815)
Eur J Immunol. 2015 Jan;45(1):142-52. (PMID: 25287052)
Front Immunol. 2015 Nov 05;6:565. (PMID: 26594215)
Neurochem Int. 2011 Dec;59(8):1155-62. (PMID: 22032971)
J Neuroimmunol. 2019 Dec 15;337:577070. (PMID: 31683117)
Eur J Immunol. 2016 Aug;46(8):1984-96. (PMID: 27325505)
Endocr J. 2010;57(7):595-601. (PMID: 20453397)
Antioxid Redox Signal. 2012 Apr 1;16(7):705-43. (PMID: 21955027)
J Neurochem. 2003 Jul;86(1):1-12. (PMID: 12807419)
Nature. 2018 Apr;556(7701):332-338. (PMID: 29643512)
J Neuroimmune Pharmacol. 2015 Dec;10(4):528-46. (PMID: 25946987)
Mol Nutr Food Res. 2008 Nov;52(11):1316-23. (PMID: 18481333)
Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E6065-E6074. (PMID: 29895691)
Anal Biochem. 1979 Jun;95(2):351-8. (PMID: 36810)
Front Immunol. 2017 Oct 16;8:1198. (PMID: 29085356)
Neurotherapeutics. 2017 Jan;14(1):199-211. (PMID: 27718209)
Eur J Pharmacol. 2008 Jul 28;589(1-3):53-7. (PMID: 18538761)
Curr Neuropharmacol. 2016;14(2):155-64. (PMID: 26639457)
Handb Clin Neurol. 2014;122:3-14. (PMID: 24507511)
J Mol Med (Berl). 2018 Dec;96(12):1279-1292. (PMID: 30386908)
J Immunol. 2006 Apr 1;176(7):4173-81. (PMID: 16547254)
Curr Rheumatol Rev. 2019;15(2):123-134. (PMID: 30324883)
Metallomics. 2017 Dec 1;9(12):1703-1734. (PMID: 29168872)
Neural Regen Res. 2019 Dec;14(12):2088-2090. (PMID: 31397344)
J Neurol Neurosurg Psychiatry. 2008 Nov;79(11):1230-5. (PMID: 18535027)
Clin Pharmacol Ther. 2017 Feb;101(2):230-238. (PMID: 27859024)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Br J Pharmacol. 2011 Oct;164(4):1079-106. (PMID: 21371012)
Chemosphere. 2007 Jul;68(8):1542-7. (PMID: 17448523)
Atherosclerosis. 2002 Apr;161(2):381-6. (PMID: 11888521)
J Inorg Biochem. 2015 Dec;153:1-12. (PMID: 26398431)
Arch Immunol Ther Exp (Warsz). 2017 Aug;65(4):325-338. (PMID: 28299403)
Biologics. 2013;7:247-58. (PMID: 24324326)
J Autoimmun. 2014 Nov;54:1-7. (PMID: 25308417)
J Nutr. 2011 Sep;141(9):1754-61. (PMID: 21775527)
Int Immunopharmacol. 2016 Jul;36:51-58. (PMID: 27111514)
Lancet. 2012 Mar 31;379(9822):1256-68. (PMID: 22381456)
Nat Commun. 2018 Jun 8;9(1):2223. (PMID: 29884801)
Brain Behav Immun. 2010 May;24(4):641-51. (PMID: 20138983)
World J Gastroenterol. 2017 Jun 7;23(21):3850-3863. (PMID: 28638225)
Semin Neurol. 2016 Apr;36(2):115-27. (PMID: 27116718)
فهرسة مساهمة: Keywords: experimental autoimmune encephalomyelitis; inflammasome; microglia; multiple sclerosis; selenium
المشرفين على المادة: 0 (Anti-Inflammatory Agents)
0 (Inflammasomes)
0 (Myelin-Oligodendrocyte Glycoprotein)
0 (NLR Family, Pyrin Domain-Containing 3 Protein)
33X04XA5AT (Lactic Acid)
H6241UJ22B (Selenium)
تواريخ الأحداث: Date Created: 20201116 Date Completed: 20210531 Latest Revision: 20231112
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7664308
DOI: 10.3389/fimmu.2020.571844
PMID: 33193354
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2020.571844